# EDGAR Filing Document

**Accession Number:** 0001503802
**File Stem:** 0001213900-23-011440
**Filing Date:** 2023-2
**Character Count:** 30822
**Document Hash:** a51840e7478c9a0b1bea7f4148023010
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-011440.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001213900-23-011440

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 6

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**GROUP MEMBERS**: ANASTASIS NIKOLAOU

**GROUP MEMBERS**: ANDREAS HADJIMICHAEL

**GROUP MEMBERS**: MARCIN CZERNIK

**GROUP MEMBERS**: WIACZESLAW SMOLOKOWSKI

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Karyopharm Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001503802
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 263931704
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-87705
- **FILM NUMBER:** 23628108

**BUSINESS ADDRESS:**
- **STREET 1:** 85 WELLS AVENUE
- **STREET 2:** SECOND FLOOR
- **CITY:** NEWTON
- **STATE:** MA
- **ZIP:** 02459
- **BUSINESS PHONE:** 617-658-0600

**MAIL ADDRESS:**
- **STREET 1:** 85 WELLS AVENUE
- **STREET 2:** SECOND FLOOR
- **CITY:** NEWTON
- **STATE:** MA
- **ZIP:** 02459
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Chione Ltd
- **CENTRAL INDEX KEY:** 0001590232
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** G4

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** SIMOU MENARDOU 8, RIA COURT 8
- **STREET 2:** OFFICE 101, 6015
- **CITY:** LARNACA
- **STATE:** G4
- **ZIP:** CY
- **BUSINESS PHONE:** 48 (22) 840 8342

**MAIL ADDRESS:**
- **STREET 1:** SIMOU MENARDOU 8, RIA COURT 8
- **STREET 2:** OFFICE 101, 6015
- **CITY:** LARNACA
- **STATE:** G4
- **ZIP:** CY

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 8)\***

Karyopharm Therapeutics Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

48576U106

(CUSIP Number)

Simon Prisk, Esq.

150 East 58th Street, 22nd Floor

New York, NY 10155

(212) 355-3333

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

12/31/22

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

&nbsp;&nbsp;&nbsp;&nbsp;☒ Rule
 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 48576U106 13G Page 2 of 11 pages

1. NAMES
 OF REPORTING PERSONS Chione
 Ltd. I.R.S.
 IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

2. CHECK
 THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ☐ (b) ☐

3. SEC
 USE ONLY

4. CITIZENSHIP
 OR PLACE OF ORGANIZATION CYPRUS

---

| | | |
|:---|:---|:---|
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | 5. | SOLE VOTING POWER<br>0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | 6. | SHARED VOTING POWER<br>4,400,000 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | 7. | SOLE DISPOSITIVE POWER<br>0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | 8. | SHARED DISPOSITIVE POWER<br>4,400,000 |

---

9. AGGREGATE
 AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,400,000

10. CHECK
 IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ☐

11. PERCENT
 OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.9%

12. TYPE
 OF REPORTING PERSON (see instructions) CO

CUSIP No. 48576U106 13G Page 3 of 11 pages

1. NAMES
 OF REPORTING PERSONS Marcin
 Czernik I.R.S.
 IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

2. CHECK
 THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ☐ (b) ☐

3. SEC
 USE ONLY

4. CITIZENSHIP
 OR PLACE OF ORGANIZATION POLAND

---

| | | |
|:---|:---|:---|
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | 5. | SOLE VOTING POWER<br>0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | 6. | SHARED VOTING POWER<br>4,400,000 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | 7. | SOLE DISPOSITIVE POWER<br>0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | 8. | SHARED DISPOSITIVE POWER<br>4,400,000 |

---

9. AGGREGATE
 AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,400,000

10. CHECK
 IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ☒

11. PERCENT
 OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.9%

12. TYPE
 OF REPORTING PERSON (see instructions) IN,
 HC

CUSIP No. 48576U106 13G Page 4 of 11 pages

1. NAMES
 OF REPORTING PERSONS Andreas
 Hadjimichael I.R.S.
 IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

2. CHECK
 THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ☐ (b) ☐

3. SEC
 USE ONLY

4. CITIZENSHIP
 OR PLACE OF ORGANIZATION CYPRUS

---

| | | |
|:---|:---|:---|
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | 5. | SOLE VOTING POWER<br>0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | 6. | SHARED VOTING POWER<br>4,400,000 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | 7. | SOLE DISPOSITIVE POWER<br>0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | 8. | SHARED DISPOSITIVE POWER<br>4,400,000 |

---

9. AGGREGATE
 AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,400,000

10. CHECK
 IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ☒

11. PERCENT
 OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.9%

12. TYPE
 OF REPORTING PERSON (see instructions) IN,
 HC

CUSIP No. 48576U106 13G Page 5 of 11 pages

1. NAMES
 OF REPORTING PERSONS Anastasis Nikolaou I.R.S.
 IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

2. CHECK
 THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ☐ (b) ☐

3. SEC
 USE ONLY

4. CITIZENSHIP
 OR PLACE OF ORGANIZATION CYPRUS

---

| | | |
|:---|:---|:---|
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | 5. | SOLE VOTING POWER<br>0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | 6. | SHARED VOTING POWER<br>4,400,000 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | 7. | SOLE DISPOSITIVE POWER<br>0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | 8. | SHARED DISPOSITIVE POWER<br>4,400,000 |

---

9. AGGREGATE
 AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,400,000

10. CHECK
 IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ☒

11. PERCENT
 OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.9%

12. TYPE
 OF REPORTING PERSON (see instructions) IN,
 HC

CUSIP No. 48576U106 13G Page 6 of 11 pages

1. NAMES
 OF REPORTING PERSONS Wiaczeslaw
 Smolokowski I.R.S.
 IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

2. CHECK
 THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ☐ (b) ☐

3. SEC
 USE ONLY

4. CITIZENSHIP
 OR PLACE OF ORGANIZATION POLAND

---

| | | |
|:---|:---|:---|
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | 5. | SOLE VOTING POWER<br>0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | 6. | SHARED VOTING POWER<br>4,400,000 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | 7. | SOLE DISPOSITIVE POWER<br>0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | 8. | SHARED DISPOSITIVE POWER<br>4,400,000 |

---

9. AGGREGATE
 AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,400,000

10. CHECK
 IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ☐

11. PERCENT
 OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.9%

12. TYPE
 OF REPORTING PERSON (see instructions) IN,
 HC

CUSIP No. 48576U106 13G Page 7 of 11 pages

**Item 1.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Karyopharm
 Therapeutics Inc.

(b) Address
 of Issuer's Principal Executive Offices 85
 Wells Avenue, 2nd Floor Newton,
 MA 02459

**Item 2.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Name
 of Person Filing This
 Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"): (i)
 Chione Ltd. ("Chione") (ii)
 Marcin Czernik (iii)
 Andreas Hadjimichael (iv) Anastasis Nikolaou (v) Wiaczeslaw Smolokowski

(b) Address
 of the Principal Office or, if none, residence (i)
 The principal office of each of the Reporting Persons (other than Mr. Smolokowski) is c/o Chione Ltd. Simou Menardou 5, Kifisia
 Court, 2nd Floor, Flat/Office 225, 6015 Larnaca, Cyprus. (ii)
 The residence address of Mr. Smolokowski is Chalet Lenotchka, Chemin des Marais 1, Chesieres, Switzerland.

(c) Citizenship (i)
 Chione is a Cyprus corporation. (ii)
 Messrs. Hadjimichael and Anastasis Nikolaou are citizens of the Republic of Cyprus. (iii)
 Messrs. Czernik and Smolokowski are citizens of the Republic of Poland.

(d) Title
 of Class of Securities Common
 Stock

(e) CUSIP
 Number 48576U106

CUSIP No. 048576U106 13G Page 8 of 11 pages

**Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

Not applicable**.**

**Item 4. Ownership.**

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

---

| | |
|:---|:---|
| (a) | Amount beneficially owned: 4,400,000 shares. These shares of Common Stock are owned directly by Chione. Chione's directors, Marcin Czernik, Andreas Hadjimichael and Anastasis Nikolaou, and its sole stockholder, Wiaczeslaw Smolokowski, may be deemed to share voting and investment power and beneficial ownership of such shares of Common Stock. Each of such directors and stockholder disclaims such voting and investment power and beneficial ownership |
| (b) | Percent of class: 3.9%. See item 4(a) above. The percentage set forth in Row (11) of the cover page for each of the Reporting Persons is based on the 113,213,167 shares of Common Stock outstanding as of December 15, 2022, as reported in the Issuer's Registration Statement on Form S-3 filed with the Securities and Exchange Commission on December 23, 2022. |
| (c) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Number of shares as to which the person has:<br><u>Chione</u> |
|  | (i) Sole power to vote or to direct the vote 0. |
|  | (ii) Shared power to vote or to direct the vote 4,400,000. |
|  | (iii) Sole power to dispose or to direct the disposition of 0 |
|  | (iv) Shared power to dispose or to direct the disposition of 4,400,000 |
|  | <u>Mr. Czernik</u> |

---

---

| |
|:---|
| (i) Sole power to vote or to direct the vote 0. |
| (ii) Shared power to vote or to direct the vote 4,400,000. |
| (iii) Sole power to dispose or to direct the disposition of 0 |
| (iv) Shared power to dispose or to direct the disposition of 4,400,000 |

---

CUSIP No. 048576U106 13G Page 9 of 11 pages

---

| |
|:---|
| <u>Mr. Hadjimichael</u> |
| (i) Sole power to vote or to direct the vote 0. |
| (ii) Shared power to vote or to direct the vote 4,400,000. |
| (iii) Sole power to dispose or to direct the disposition of 0 |
| (iv) Shared power to dispose or to direct the disposition of 4,400,000 |
| <u>Mr. Nikolaou</u> |
| (i) Sole power to vote or to direct the vote 0. |
| <br>(ii) Shared power to vote or to direct the vote 4,400,000.  |
| (iii) Sole power to dispose or to direct the disposition of 0 |
| <br>(iv) Shared power to dispose or to direct the disposition of 4,400,000 |

---

CUSIP No. 048576U106 13G Page 10 of 11 pages

---

| |
|:---|
| <u>Mr. Smolokowski</u> |
| (i) Sole power to vote or to direct the vote 0. |
| (ii) Shared power to vote or to direct the vote 4,400,000. |
| (iii) Sole power to dispose or to direct the disposition of 0 |
| (iv) Shared power to dispose or to direct the disposition of 4,400,000 |

---

**See item 4(a) above.**

**Item 5. Ownership of Five Percent or Less of a Class.**

Not applicable.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.**

Not applicable.

**Item 8. Identification and Classification of Members of the Group.**

Not applicable.

**Item 9. Notice of Dissolution of Group.**

Not applicable.

**Item 10. Certification.**

Not applicable.

CUSIP No. 048576U106 13G Page 11 of 11 pages

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

<u>February 14, 2023</u> <br> Date

---

| | |
|:---|:---|
| Chione Limited, by <u>/s/ Shalom Leaf,</u> | Chione Limited, by <u>/s/ Shalom Leaf,</u> |
|  | as attorney-in-fact |
| Marcin Czernik, by <u>/s/ Shalom Leaf,</u> | Marcin Czernik, by <u>/s/ Shalom Leaf,</u> |
|  | as attorney-in-fact |
| Andreas Hadjimichael, by <u>/s/ Shalom Leaf,</u> | Andreas Hadjimichael, by <u>/s/ Shalom Leaf,</u> |
|  | as attorney-in-fact |
| Anastasis Nikolaou, by <u>/s/ Shalom Leaf,</u> | Anastasis Nikolaou, by <u>/s/ Shalom Leaf,</u> |
|  | as attorney-in-fact |
| Wiaczeslaw Smolokowski, by <u>/s/ Shalom Leaf,</u> | Wiaczeslaw Smolokowski, by <u>/s/ Shalom Leaf,</u> |
|  | as attorney-in-fact |

---

<u>Exhibit Index</u>

---

| |
|:---|
| Exhibit 24.1 – [Power of Attorney, dated as of February 13, 2023, made by Marcin Czernik and Chione Limited in favor of Shalom Leaf\*](ea173459ex24-1_karyo.htm) |
| Exhibit 24.2 – [Power of Attorney, dated as of February 13, 2023, made by Andreas Hadjimichael and Chione Limited in favor of Shalom Leaf\*](ea173459ex24-2_karyo.htm) |
| Exhibit 24.3 – [Power of Attorney, dated February 13, 2023, made by Wiaczeslaw Smolokowski in favor of Shalom Leaf\*](ea173459ex24-3_karyo.htm) |
| Exhibit 24.4 – [Power of Attorney, dated February 13, 2023, made by Anastasis Nikolaou and Chione Limited in favor of Shalom Leaf\*](ea173459ex24-4_karyo.htm) |
| Exhibit 99.1 – [Joint Filing Agreement, dated February 13, 2023, among the Reporting Persons](ea173459ex99-1_karyo.htm) |

---

## Exhibit 24.1

**Exhibit 24.1**

**LIMITED POWER OF ATTORNEY**

The undersigned, Marcin Czernik, hereby appoints Shalom Leaf as his attorney-in-fact (i) for and on behalf of the undersigned, including, without limitation, in my current or future capacity as a director and, if applicable, as an officer of Chione Limited (the "Company"), and (ii) for and on behalf of the Company, in each case, in respect of (A) any current or future direct or indirect beneficial ownership of, or pecuniary interest in (whether or not such beneficial ownership or pecuniary interest is disclaimed), securities of Karyopharm Therapeutics Inc., including any successor entity ("KTI"), and (B) any other status or transaction of or involving the undersigned and/or the Company requiring any filing or report pursuant to the Securities Exchange Act of 1934 and the rules and regulations thereunder or applicable thereto (the "Exchange Act") in respect of such securities, including, without limitation, pursuant to Section 13 or 16 of the Exchange Act. Such appointment as attorney-in-fact shall include, without limitation, the power and authority:

&nbsp;&nbsp;&nbsp;&nbsp;1. to execute and file a Form ID on behalf of the undersigned and otherwise to secure any codes required
in order for the undersigned to be able to file with the U.S. Securities and Exchange Commission's Edgar system;

&nbsp;&nbsp;&nbsp;&nbsp;2. to execute and file any Form 3, Form 4, or Form 5, Schedule 13G or 13D, any amendments
to any such Form or Schedule, and any filing agreements related to securities of KTI on behalf of the undersigned and/or the Company;

&nbsp;&nbsp;&nbsp;&nbsp;3. to seek and obtain information on behalf of, and as the representative of the undersigned and/or the Company,
from any and all persons, including, without limitation, representatives of the Company and KTI, in connection with the foregoing; and

&nbsp;&nbsp;&nbsp;&nbsp;4. to do and perform any and all acts and things, including, without limitation, to execute, submit and file
such agreements, instruments, forms and other documents, to incur such expenses, as may be necessary or desirable, in the sole discretion
of such attorney-in-fact, in connection with the foregoing, it being understood that the documents executed by such attorney-in-fact pursuant
to this Limited Power of Attorney shall be in such form and shall contain such information as such attorney-in-fact may approve in such
attorney-in-fact's sole discretion.

The undersigned acknowledges that said attorney-in-fact is not assuming any of my responsibilities to comply with the Exchange Act.

Said attorney-in-fact may (i) act in reliance upon the signature below; and (ii) assume that any person, whether as an individual or as a person who has been designated by the Company or KTI or any other person to give any written instructions, notice or receipt, or make any statements in connection with the foregoing matters (or any of them) has been duly authorized to do so.

Said attorney-in-fact shall have no duty to make inquiry as to the genuineness, accuracy or validity of any statements or instructions or any signatures or instructions.

This Limited Power of Attorney will remain in effect until February 13, 2024 or until such earlier time as a written revocation of this Limited Power of Attorney is delivered to said attorney-in-fact at his then current address.

The undersigned is signing this Limited Power of Attorney as of February 13, 2023.

---

| |
|:---|
| /s/ Marcin Czernik |
| Marcin Czernik, individually, including in his<br> capacity as an officer and/or director of the Company<br> (as applicable), and on behalf of the Company |

---

## Exhibit 24.2

**Exhibit 24.2**

**LIMITED POWER OF ATTORNEY**

The undersigned, Andreas Hadjimichael, hereby appoints Shalom Leaf as his attorney-in-fact (i) for and on behalf of the undersigned, including, without limitation, in my current or future capacity as a director and, if applicable, as an officer of Chione Limited (the "Company"), and (ii) for and on behalf of the Company, in each case, in respect of (A) any current or future direct or indirect beneficial ownership of, or pecuniary interest in (whether or not such beneficial ownership or pecuniary interest is disclaimed), securities of Karyopharm Therapeutics Inc., including any successor entity ("KTI"), and (B) any other status or transaction of or involving the undersigned and/or the Company requiring any filing or report pursuant to the Securities Exchange Act of 1934 and the rules and regulations thereunder or applicable thereto (the "Exchange Act") in respect of such securities, including, without limitation, pursuant to Section 13 or 16 of the Exchange Act. Such appointment as attorney-in-fact shall include, without limitation, the power and authority:

&nbsp;&nbsp;&nbsp;&nbsp;1. to execute and file a Form ID on behalf of the undersigned and otherwise to secure any codes required
in order for the undersigned to be able to file with the U.S. Securities and Exchange Commission's Edgar system;

&nbsp;&nbsp;&nbsp;&nbsp;2. to execute and file any Form 3, Form 4, or Form 5, Schedule 13G or 13D, any amendments
to any such Form or Schedule, and any filing agreements related to securities of KTI on behalf of the undersigned and/or the Company;

&nbsp;&nbsp;&nbsp;&nbsp;3. to seek and obtain information on behalf of, and as the representative of the undersigned and/or the Company,
from any and all persons, including, without limitation, representatives of the Company and KTI, in connection with the foregoing; and

&nbsp;&nbsp;&nbsp;&nbsp;4. to do and perform any and all acts and things, including, without limitation, to execute, submit and file
such agreements, instruments, forms and other documents, to incur such expenses, as may be necessary or desirable, in the sole discretion
of such attorney-in-fact, in connection with the foregoing, it being understood that the documents executed by such attorney-in-fact pursuant
to this Limited Power of Attorney shall be in such form and shall contain such information as such attorney-in-fact may approve in such
attorney-in-fact's sole discretion.

The undersigned acknowledges that said attorney-in-fact is not assuming any of my responsibilities to comply with the Exchange Act.

Said attorney-in-fact may (i) act in reliance upon the signature below; and (ii) assume that any person, whether as an individual or as a person who has been designated by the Company or KTI or any other person to give any written instructions, notice or receipt, or make any statements in connection with the foregoing matters (or any of them) has been duly authorized to do so.

Said attorney-in-fact shall have no duty to make inquiry as to the genuineness, accuracy or validity of any statements or instructions or any signatures or instructions.

This Limited Power of Attorney will remain in effect until February 13, 2024 or until such earlier time as a written revocation of this Limited Power of Attorney is delivered to said attorney-in-fact at his then current address.

The undersigned is signing this Limited Power of Attorney as of February 13, 2023.

---

| |
|:---|
| /s/ Andreas Hadjimichael |
| Andreas Hadjimichael, individually, including in his <br> capacity as an officer and/or director of the Company<br> (as applicable), and on behalf of the Company |

---

## Exhibit 24.3

**Exhibit 24.3**

**LIMITED POWER OF ATTORNEY**

The undersigned, Wiaczeslaw Smolokowski, hereby appoints Shalom Leaf as his attorney-in-fact for and on behalf of the undersigned, in respect of (A) any current or future direct or indirect beneficial ownership of, or pecuniary interest in (whether or not such beneficial ownership or pecuniary interest is disclaimed), securities of Karyopharm Therapeutics Inc., including any successor entity ("KTI"), and (B) any other status, including, if applicable, as an officer or director of Chione Limited (the "Company"), or transaction of or involving the undersigned and/or the Company requiring any filing or report pursuant to the Securities Exchange Act of 1934 and the rules and regulations thereunder or applicable thereto (the "Exchange Act") in respect of such securities, including, without limitation, pursuant to Section 13 or 16 of the Exchange Act. Such appointment as attorney-in-fact shall include, without limitation, the power and authority:

&nbsp;&nbsp;&nbsp;&nbsp;1. to execute and file a Form ID on behalf of the undersigned and otherwise to secure any codes required
in order for the undersigned to be able to file with the U.S. Securities and Exchange Commission's Edgar system;

&nbsp;&nbsp;&nbsp;&nbsp;2. to execute and file any Form 3, Form 4, or Form 5, Schedule 13G or 13D, any amendments
to any such Form or Schedule, and any filing agreements related to securities of KTI on behalf of the undersigned and/or the Company;

&nbsp;&nbsp;&nbsp;&nbsp;3. to seek and obtain information on behalf of, and as the representative of the undersigned and/or the Company,
from any and all persons, including, without limitation, representatives of the Company and KTI, in connection with the foregoing; and

&nbsp;&nbsp;&nbsp;&nbsp;4. to do and perform any and all acts and things, including, without limitation, to execute, submit and file
such agreements, instruments, forms and other documents, to incur such expenses, as may be necessary or desirable, in the sole discretion
of such attorney-in-fact, in connection with the foregoing, it being understood that the documents executed by such attorney-in-fact pursuant
to this Limited Power of Attorney shall be in such form and shall contain such information as such attorney-in-fact may approve in such
attorney-in-fact's sole discretion.

The undersigned acknowledges that said attorney-in-fact is not assuming any of my responsibilities to comply with the Exchange Act.

Said attorney-in-fact may (i) act in reliance upon the signature below; and (ii) assume that any person, whether as an individual or as a person who has been designated by the Company or KTI or any other person to give any written instructions, notice or receipt, or make any statements in connection with the foregoing matters (or any of them) has been duly authorized to do so.

Said attorney-in-fact shall have no duty to make inquiry as to the genuineness, accuracy or validity of any statements or instructions or any signatures or instructions.

This Limited Power of Attorney will remain in effect until February 13, 2024 or until such earlier time as a written revocation of this Limited Power of Attorney is delivered to said attorney-in-fact at his then current address.

The undersigned is signing this Limited Power of Attorney as of February 13, 2023.

---

| |
|:---|
| /s/ Wiaczeslaw Smolokowski |
| Wiaczeslaw Smolokowski |

---

## Exhibit 24.4

**Exhibit 24.4**

**LIMITED POWER OF ATTORNEY**

The undersigned, Anastasis Nikolaou, hereby appoints Shalom Leaf as his attorney-in-fact (i) for and on behalf of the undersigned, including, without limitation, in my current or future capacity as a director and, if applicable, as an officer of Chione Limited (the "Company"), and (ii) for and on behalf of the Company, in each case, in respect of (A) any current or future direct or indirect beneficial ownership of, or pecuniary interest in (whether or not such beneficial ownership or pecuniary interest is disclaimed), securities of Karyopharm Therapeutics Inc., including any successor entity ("KTI"), and (B) any other status or transaction of or involving the undersigned and/or the Company requiring any filing or report pursuant to the Securities Exchange Act of 1934 and the rules and regulations thereunder or applicable thereto (the "Exchange Act") in respect of such securities, including, without limitation, pursuant to Section 13 or 16 of the Exchange Act. Such appointment as attorney-in-fact shall include, without limitation, the power and authority:

&nbsp;&nbsp;&nbsp;&nbsp;1. to execute and file a Form ID on behalf of the undersigned and otherwise to secure any codes required
in order for the undersigned to be able to file with the U.S. Securities and Exchange Commission's Edgar system;

&nbsp;&nbsp;&nbsp;&nbsp;2. to execute and file any Form 3, Form 4, or Form 5, Schedule 13G or 13D, any amendments
to any such Form or Schedule, and any filing agreements related to securities of KTI on behalf of the undersigned and/or the Company;

&nbsp;&nbsp;&nbsp;&nbsp;3. to seek and obtain information on behalf of, and as the representative of the undersigned and/or the Company,
from any and all persons, including, without limitation, representatives of the Company and KTI, in connection with the foregoing; and

&nbsp;&nbsp;&nbsp;&nbsp;4. to do and perform any and all acts and things, including, without limitation, to execute, submit and file
such agreements, instruments, forms and other documents, to incur such expenses, as may be necessary or desirable, in the sole discretion
of such attorney-in-fact, in connection with the foregoing, it being understood that the documents executed by such attorney-in-fact pursuant
to this Limited Power of Attorney shall be in such form and shall contain such information as such attorney-in-fact may approve in such
attorney-in-fact's sole discretion.

The undersigned acknowledges that said attorney-in-fact is not assuming any of my responsibilities to comply with the Exchange Act.

Said attorney-in-fact may (i) act in reliance upon the signature below; and (ii) assume that any person, whether as an individual or as a person who has been designated by the Company or KTI or any other person to give any written instructions, notice or receipt, or make any statements in connection with the foregoing matters (or any of them) has been duly authorized to do so.

Said attorney-in-fact shall have no duty to make inquiry as to the genuineness, accuracy or validity of any statements or instructions or any signatures or instructions.

This Limited Power of Attorney will remain in effect until February 13, 2024 or until such earlier time as a written revocation of this Limited Power of Attorney is delivered to said attorney-in-fact at his then current address.

The undersigned is signing this Limited Power of Attorney as of February 13, 2023.

---

| |
|:---|
| /s/ Anastasis Nikolaou |
| Anastasis Nikolaou, individually, including in his<br> capacity as an officer and/or director of the Company <br> (as applicable), and on behalf of the Company |

---

## Exhibit 99.1

**Exhibit 99.1**

**JOINT FILING AGREEMENT**

The undersigned hereby agree that Amendment No. 8 to the Schedule 13G, dated as of February 14, 2023, with respect to the Common Stock of Karyopharm Therapeutics Inc. is, and any amendments thereto, any Schedule 13D with respect to such Common Stock, and any amendments thereto, signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(f) under the Securities Exchange Act of 1934.

---

| | |
|:---|:---|
| Dated: February 14, 2023 | Chione Ltd., by <u>/s/ Shalom Leaf,</u> |
|  | as attorney-in-fact |
|  | Marcin Czernik, by <u>/s/ Shalom Leaf,</u> |
|  | as attorney-in-fact |
|  | Andreas Hadjimichael, by <u>/s/ Shalom Leaf,</u> |
|  | as attorney-in-fact |
|  | Anastasios Nikolaou, by <u>/s/ Shalom Leaf,</u> |
|  | as attorney-in- fact |
|  | Wiaczeslaw Smolokowski, by <u>/s/ Shalom Leaf,</u> |
|  | as attorney-in-fact |

---